ES2524379T3 - Medicamento con contenido en miramistina - Google Patents
Medicamento con contenido en miramistina Download PDFInfo
- Publication number
- ES2524379T3 ES2524379T3 ES11708184.4T ES11708184T ES2524379T3 ES 2524379 T3 ES2524379 T3 ES 2524379T3 ES 11708184 T ES11708184 T ES 11708184T ES 2524379 T3 ES2524379 T3 ES 2524379T3
- Authority
- ES
- Spain
- Prior art keywords
- propyl
- weight
- myristoylamino
- additionally contains
- medication
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 31
- 229940079593 drug Drugs 0.000 title claims abstract description 16
- JQQZCIIDNVIQKO-UHFFFAOYSA-N benzyl-dimethyl-[3-(tetradecanoylamino)propyl]azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC1=CC=CC=C1 JQQZCIIDNVIQKO-UHFFFAOYSA-N 0.000 title abstract description 9
- -1 dimethyl (3- [myristoylamino] -propyl) -aminoxide Chemical compound 0.000 claims abstract description 8
- 239000008063 pharmaceutical solvent Substances 0.000 claims abstract description 8
- 150000004682 monohydrates Chemical class 0.000 claims abstract description 7
- 241001465754 Metazoa Species 0.000 claims description 32
- 238000002360 preparation method Methods 0.000 claims description 29
- 238000011282 treatment Methods 0.000 claims description 27
- 239000002674 ointment Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 11
- 238000011321 prophylaxis Methods 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 230000002421 anti-septic effect Effects 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 5
- HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 claims description 4
- 229940064004 antiseptic throat preparations Drugs 0.000 claims description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 229960002537 betamethasone Drugs 0.000 claims description 3
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 2
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 claims description 2
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 2
- 229960004150 aciclovir Drugs 0.000 claims description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 2
- 229960003150 bupivacaine Drugs 0.000 claims description 2
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims description 2
- 229960004022 clotrimazole Drugs 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims description 2
- 229960003957 dexamethasone Drugs 0.000 claims description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 2
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 claims description 2
- 229960001347 fluocinolone acetonide Drugs 0.000 claims description 2
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 claims description 2
- 229960002475 halometasone Drugs 0.000 claims description 2
- GGXMRPUKBWXVHE-MIHLVHIWSA-N halometasone Chemical compound C1([C@@H](F)C2)=CC(=O)C(Cl)=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O GGXMRPUKBWXVHE-MIHLVHIWSA-N 0.000 claims description 2
- 229960000890 hydrocortisone Drugs 0.000 claims description 2
- 229960004125 ketoconazole Drugs 0.000 claims description 2
- 229960004194 lidocaine Drugs 0.000 claims description 2
- 239000003589 local anesthetic agent Substances 0.000 claims description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 2
- 229960000282 metronidazole Drugs 0.000 claims description 2
- 229960001528 oxymetazoline Drugs 0.000 claims description 2
- 229960001802 phenylephrine Drugs 0.000 claims description 2
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims description 2
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 claims description 2
- 229960000395 phenylpropanolamine Drugs 0.000 claims description 2
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 claims description 2
- 229960003908 pseudoephedrine Drugs 0.000 claims description 2
- 229960000888 rimantadine Drugs 0.000 claims description 2
- 229960005294 triamcinolone Drugs 0.000 claims description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims description 2
- GOZBHBFUQHMKQB-UHFFFAOYSA-N trimecaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=C(C)C=C1C GOZBHBFUQHMKQB-UHFFFAOYSA-N 0.000 claims description 2
- 229950002569 trimecaine Drugs 0.000 claims description 2
- 235000013311 vegetables Nutrition 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 229960000833 xylometazoline Drugs 0.000 claims description 2
- VEPZOLKTNZOTTQ-UHFFFAOYSA-N 1-butyl-n-(2,4,6-trimethylphenyl)pyrrolidine-2-carboxamide Chemical compound CCCCN1CCCC1C(=O)NC1=C(C)C=C(C)C=C1C VEPZOLKTNZOTTQ-UHFFFAOYSA-N 0.000 claims 1
- ZWFDPYBGSBMYPB-UHFFFAOYSA-N 3-(tetradecanoylamino)propylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC(=O)NCCC[NH3+] ZWFDPYBGSBMYPB-UHFFFAOYSA-N 0.000 claims 1
- 239000000604 anti-edema agent Substances 0.000 claims 1
- 150000003840 hydrochlorides Chemical class 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- IFYDWYVPVAMGRO-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]tetradecanamide Chemical compound CCCCCCCCCCCCCC(=O)NCCCN(C)C IFYDWYVPVAMGRO-UHFFFAOYSA-N 0.000 abstract description 4
- 239000000203 mixture Substances 0.000 description 27
- 238000012360 testing method Methods 0.000 description 25
- 230000000694 effects Effects 0.000 description 17
- 241000283973 Oryctolagus cuniculus Species 0.000 description 15
- 230000000052 comparative effect Effects 0.000 description 14
- 239000000243 solution Substances 0.000 description 12
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 210000004087 cornea Anatomy 0.000 description 9
- 206010052428 Wound Diseases 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 238000011835 investigation Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 241000711573 Coronaviridae Species 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 210000004877 mucosa Anatomy 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 241000700198 Cavia Species 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 4
- 229940073608 benzyl chloride Drugs 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010052122 Dellen Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 229940095731 candida albicans Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- JWRMHDSINXPDHB-OJAGFMMFSA-N flumethasone pivalate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)COC(=O)C(C)(C)C)(O)[C@@]2(C)C[C@@H]1O JWRMHDSINXPDHB-OJAGFMMFSA-N 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 208000015891 sexual disease Diseases 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000001150 spermicidal effect Effects 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 210000003708 urethra Anatomy 0.000 description 3
- 229910002012 Aerosil® Inorganic materials 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 241000700112 Chinchilla Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000589970 Spirochaetales Species 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 230000003501 anti-edematous effect Effects 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 231100000086 high toxicity Toxicity 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000000622 irritating effect Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- QEALYLRSRQDCRA-UHFFFAOYSA-N myristamide Chemical compound CCCCCCCCCCCCCC(N)=O QEALYLRSRQDCRA-UHFFFAOYSA-N 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 206010034674 peritonitis Diseases 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 208000006379 syphilis Diseases 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- ZILVNHNSYBNLSZ-UHFFFAOYSA-N 2-(diaminomethylideneamino)guanidine Chemical compound NC(N)=NNC(N)=N ZILVNHNSYBNLSZ-UHFFFAOYSA-N 0.000 description 1
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- 241000224422 Acanthamoeba Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 206010019973 Herpes virus infection Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010048218 Xeroderma Diseases 0.000 description 1
- 101150093411 ZNF143 gene Proteins 0.000 description 1
- VIDBLJZUVIZVQP-UHFFFAOYSA-N [Cl-].C(CCCCCCCCCCCCC)(=O)NCCC[N+](CC1=CC=CC=C1)(C)C.[Cl-].C(C1=CC=CC=C1)[N+](CCCNC(CCCCCCCCCCCCC)=O)(C)C Chemical compound [Cl-].C(CCCCCCCCCCCCC)(=O)NCCC[N+](CC1=CC=CC=C1)(C)C.[Cl-].C(C1=CC=CC=C1)[N+](CCCNC(CCCCCCCCCCCCC)=O)(C)C VIDBLJZUVIZVQP-UHFFFAOYSA-N 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- YEAYHNRJRKXWNV-UHFFFAOYSA-O benzyl-dimethyl-[3-(tetradecanoylamino)propyl]azanium Chemical compound CCCCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC1=CC=CC=C1 YEAYHNRJRKXWNV-UHFFFAOYSA-O 0.000 description 1
- 206010005159 blepharospasm Diseases 0.000 description 1
- 230000000744 blepharospasm Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000001894 hemadsorption Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 210000000003 hoof Anatomy 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002718 inhibitory effect on inflammation Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229960005016 naphazoline Drugs 0.000 description 1
- 208000015386 nasopharyngeal disease Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000002161 passivation Methods 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/131—Amines acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Otolaryngology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2010/001056 WO2011100994A1 (de) | 2010-02-19 | 2010-02-19 | Arzneimittel enthaltend myramistin |
| WOPCT/EP2010/001056 | 2010-02-19 | ||
| PCT/EP2011/000691 WO2011101113A1 (de) | 2010-02-19 | 2011-02-15 | Arzneimittel enthaltend myramistin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2524379T3 true ES2524379T3 (es) | 2014-12-05 |
Family
ID=42668884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11708184.4T Active ES2524379T3 (es) | 2010-02-19 | 2011-02-15 | Medicamento con contenido en miramistina |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP2536400B1 (enExample) |
| JP (1) | JP5746224B2 (enExample) |
| KR (1) | KR101744895B1 (enExample) |
| CN (1) | CN102869354B (enExample) |
| AU (1) | AU2011217530B2 (enExample) |
| BR (1) | BR112012020828B1 (enExample) |
| CY (1) | CY1115833T1 (enExample) |
| DK (1) | DK2536400T3 (enExample) |
| EA (1) | EA022283B1 (enExample) |
| ES (1) | ES2524379T3 (enExample) |
| GE (1) | GEP20135942B (enExample) |
| HR (1) | HRP20141173T1 (enExample) |
| IL (1) | IL221501A (enExample) |
| MD (1) | MD4411C1 (enExample) |
| MX (1) | MX2012009646A (enExample) |
| PL (1) | PL2536400T3 (enExample) |
| PT (1) | PT2536400E (enExample) |
| SI (1) | SI2536400T1 (enExample) |
| UA (1) | UA103968C2 (enExample) |
| WO (2) | WO2011100994A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014175757A1 (ru) * | 2013-04-22 | 2014-10-30 | Общество с ограниченной ответственностью "Нанобиотех" | Антисептический ветеринарный препарат и способы его использования |
| RU2542376C1 (ru) * | 2013-07-30 | 2015-02-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Средство для лечения гнойно-воспалительных процессов мягких тканей и слизистых оболочек |
| CN109456218A (zh) * | 2018-12-17 | 2019-03-12 | 山东诚汇双达药业有限公司 | 一种盐酸三甲卡因的生产方法 |
| GB202003240D0 (en) * | 2020-03-05 | 2020-04-22 | Ecosynth Nv | Antiviral treatment |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2459062A (en) | 1944-02-08 | 1949-01-11 | American Cyanamid Co | Quaternary ammonium compounds |
| US4093711A (en) * | 1976-08-13 | 1978-06-06 | Noxell Corporation | Oral hygiene |
| SU1796185A1 (ru) | 1990-06-23 | 1993-02-23 | Adolina P Rudko | Фунгицид 2 |
| WO1993000892A1 (fr) | 1991-07-10 | 1993-01-21 | Jury Semenovich Krivoshein | Preparation pharmaceutique |
| US5393491A (en) | 1993-09-22 | 1995-02-28 | Alcon Laboratories, Inc. | Use of amidoamines in ophthalmic compositions |
| UA30143C2 (uk) * | 1997-12-30 | 2001-11-15 | Юрій Семенович Кривошеін | Лікувальний препарат для профілактики та лікування інфекційних та запальних захворювань |
| RU2157214C2 (ru) | 1998-04-16 | 2000-10-10 | Государственный научный центр лекарственных средств | Противовоспалительное и антимикробное лекарственное средство для местного применения |
| RU2161961C1 (ru) * | 2000-03-17 | 2001-01-20 | Кривошеин Юрий Семенович | Лекарственный препарат |
| RU2177314C2 (ru) | 2000-03-22 | 2001-12-27 | Кривошеин Юрий Семенович | Состав с антисептическими, репаративными и болеутоляющими свойствами |
| RU2173142C1 (ru) | 2000-04-18 | 2001-09-10 | Кривошеин Юрий Семенович | Вагинальный контрацептив |
| RU2164135C1 (ru) | 2000-04-27 | 2001-03-20 | Рудько Адолина Петровна | Глазной антисептик |
| RU2184534C2 (ru) | 2000-04-27 | 2002-07-10 | Рудько Адолина Петровна | Антисептические таблетки |
| RU2185157C2 (ru) | 2000-06-26 | 2002-07-20 | Рудько Адолина Петровна | Средство для лечения ожоговых ран |
| RU2185156C2 (ru) | 2000-06-26 | 2002-07-20 | Рудько Адолина Петровна | Интраназальный антисептик |
| RU2188005C2 (ru) | 2000-10-04 | 2002-08-27 | Рудько Адолина Петровна | Состав для антисептической обработки кожи рук и операционного поля |
| US20040033208A1 (en) | 2000-12-20 | 2004-02-19 | Cagle Gerald D. | Antifungal compositions containing an antibiotic and one or more amidoamines |
| WO2002049627A2 (en) * | 2000-12-20 | 2002-06-27 | Alcon, Inc. | Antifungal compositions containing an antibiotic and one or more amidoamines |
| WO2002049633A2 (en) | 2000-12-20 | 2002-06-27 | Alcon, Inc. | Use of amidoamines to treat or prevent acanthamoeba and fungal infections |
| RU2234313C1 (ru) * | 2003-06-04 | 2004-08-20 | Кривошеин Юрий Семенович | Средство инактивации коронавирусов |
| RU2005100533A (ru) * | 2005-01-13 | 2006-06-20 | Открытое акционерное общество "Система-Венчур" (ОАО "Система-Венчур") (RU) | Средство для ускорения заживления раны |
| US20070264226A1 (en) | 2006-05-10 | 2007-11-15 | Karagoezian Hampar L | Synergistically enhanced disinfecting solutions |
| CN101562971A (zh) * | 2006-05-10 | 2009-10-21 | S.K.药物公司 | 协同增强的消毒溶液 |
| CN101100432B (zh) * | 2006-07-04 | 2010-08-04 | 中国人民解放军军事医学科学院毒物药物研究所 | 苯甲基二甲基[3-(肉豆蔻酰胺基)丙基]氯化铵的合成方法 |
| DE102008039234A1 (de) * | 2007-10-29 | 2009-05-07 | Neudecker & Jolitz Gmbh & Co. | Motorisch betriebener Türöffner und Motor für einen Türöffner |
| UA30143U (en) | 2007-11-14 | 2008-02-11 | Валерий Михайлович Шарапов | Piezoelectric transformer |
| DE102008039254A1 (de) * | 2008-08-20 | 2010-02-25 | Megainpharm Gmbh | Arzneimittel |
-
2010
- 2010-02-19 WO PCT/EP2010/001056 patent/WO2011100994A1/de not_active Ceased
-
2011
- 2011-02-15 AU AU2011217530A patent/AU2011217530B2/en active Active
- 2011-02-15 ES ES11708184.4T patent/ES2524379T3/es active Active
- 2011-02-15 DK DK11708184.4T patent/DK2536400T3/en active
- 2011-02-15 EP EP11708184.4A patent/EP2536400B1/de active Active
- 2011-02-15 HR HRP20141173AT patent/HRP20141173T1/hr unknown
- 2011-02-15 CN CN201180014472.7A patent/CN102869354B/zh active Active
- 2011-02-15 SI SI201130337T patent/SI2536400T1/sl unknown
- 2011-02-15 GE GEAP201112831A patent/GEP20135942B/en unknown
- 2011-02-15 BR BR112012020828-4A patent/BR112012020828B1/pt not_active IP Right Cessation
- 2011-02-15 PT PT117081844T patent/PT2536400E/pt unknown
- 2011-02-15 WO PCT/EP2011/000691 patent/WO2011101113A1/de not_active Ceased
- 2011-02-15 KR KR1020127024396A patent/KR101744895B1/ko active Active
- 2011-02-15 EA EA201201158A patent/EA022283B1/ru unknown
- 2011-02-15 JP JP2012553213A patent/JP5746224B2/ja active Active
- 2011-02-15 MD MDA20120079A patent/MD4411C1/ro active IP Right Grant
- 2011-02-15 PL PL11708184T patent/PL2536400T3/pl unknown
- 2011-02-15 MX MX2012009646A patent/MX2012009646A/es active IP Right Grant
- 2011-02-15 UA UAA201210093A patent/UA103968C2/ru unknown
-
2012
- 2012-08-16 IL IL221501A patent/IL221501A/en active IP Right Grant
-
2014
- 2014-12-11 CY CY20141101033T patent/CY1115833T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MD4411C1 (ro) | 2016-11-30 |
| BR112012020828B1 (pt) | 2021-01-12 |
| PT2536400E (pt) | 2014-11-27 |
| KR20130018242A (ko) | 2013-02-20 |
| BR112012020828A2 (pt) | 2016-06-28 |
| PL2536400T3 (pl) | 2015-04-30 |
| JP5746224B2 (ja) | 2015-07-08 |
| SI2536400T1 (sl) | 2015-01-30 |
| KR101744895B1 (ko) | 2017-06-08 |
| CN102869354B (zh) | 2015-12-16 |
| EA201201158A1 (ru) | 2013-02-28 |
| AU2011217530A1 (en) | 2012-09-13 |
| GEP20135942B (en) | 2013-10-10 |
| CN102869354A (zh) | 2013-01-09 |
| UA103968C2 (ru) | 2013-12-10 |
| WO2011100994A1 (de) | 2011-08-25 |
| AU2011217530B2 (en) | 2014-01-16 |
| HK1179164A1 (zh) | 2013-09-27 |
| WO2011101113A1 (de) | 2011-08-25 |
| EA022283B1 (ru) | 2015-12-30 |
| MX2012009646A (es) | 2013-02-11 |
| IL221501A (en) | 2016-11-30 |
| DK2536400T3 (en) | 2014-12-15 |
| CY1115833T1 (el) | 2017-01-25 |
| HRP20141173T1 (hr) | 2015-01-30 |
| EP2536400B1 (de) | 2014-09-24 |
| EP2536400A1 (de) | 2012-12-26 |
| MD20120079A2 (en) | 2013-01-31 |
| MD4411B1 (ro) | 2016-04-30 |
| JP2013519695A (ja) | 2013-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK173078B1 (da) | Anvendelse af en lysozym-dimer og/eller en ribonuclease-dimer til fremstilling af et lægemiddel til behandling af virus- el | |
| CN1946428A (zh) | 具有治疗作用的抗微生物组合物和方法 | |
| SK285361B6 (sk) | Antimikrobiálna kompozícia a jej použitie na liečbu ochorení vyvolaných vírusom herpes simplex a iných infekčných ochorení | |
| US20040071769A1 (en) | Antimicrobial wash and carrier solutions, and uses thereof | |
| ES2524379T3 (es) | Medicamento con contenido en miramistina | |
| EA005917B1 (ru) | Вирулицидные композиции | |
| CN108420789A (zh) | 一种苯扎氯铵外用溶液及其制备方法 | |
| CN111973551A (zh) | 一种贻贝粘蛋白抑菌凝胶及其制备方法 | |
| CN111228458A (zh) | 防治阴道炎症的外用生物制剂及其制备方法 | |
| RU2161961C1 (ru) | Лекарственный препарат | |
| CN106511478A (zh) | 一种治疗犬癣的复合精油及其制备方法和应用 | |
| CN111920911B (zh) | 一种防蚊消毒剂及制备方法 | |
| CN114040756A (zh) | 疾病控制方法 | |
| RU2843470C1 (ru) | Средство по уходу за глазами животных | |
| Wahyuddin et al. | The use of an ambroxol solution to assess acute dermal irritation on rabbit skin | |
| Wutzler et al. | Comparative testing of liposomal and aqueous formulations of povidone-iodine for their angioirritative potential at the chorioallantoic membrane of ex ovo cultivated chick embryos | |
| CN112972516B (zh) | 一种用于外耳道炎的消毒产品 | |
| HK1179164B (en) | Pharmaceutical comprising myramistin | |
| UA160821U (uk) | Спосіб виготовлення серветки гелевої проти ран і опіків з покращеними ранозагоювальними властивостями | |
| RU2687745C1 (ru) | Комбинированное лекарственное средство в виде раствора для получения спрея для лечения заболеваний ротовой полости | |
| KR20240069356A (ko) | 질 칸디다증 치료용 스프레이 약학적 조성물 | |
| CA3219596A1 (en) | Compositions and uses therefor | |
| CN119326869A (zh) | 一种多肽复配中药提取物抗菌抗病毒制剂及其制备方法 | |
| DE102008039254A1 (de) | Arzneimittel | |
| CN111568886A (zh) | 一种用于治疗牛螨病的中西药复方涂膜剂及其制备方法 |